Eric J. Rubin

This study identifies trehalose as an activator of ClpC1P1P2 and ClpXP1P2 protease complexes in Mycobacterium tuberculosis, revealing a new mechanism for in vivo activation without the need for peptide activators.

This study identifies an ABC-F protein in Mycobacterium abscessus that confers resistance to linezolid and other ribosome-targeting antibiotics.

The paper develops an orally effective biotin inhibitor, C48, against Mycobacterium tuberculosis, demonstrating in vivo efficacy in a low-biotin mouse model.

This study identifies a novel mechanism by which rifampin shortens TB treatment by inhibiting Mtb RNA polymerase, leading to cell division arrest and reduced antibiotic resistance.

The paper identifies membrane permeability and efflux pumps as key mechanisms of intrinsic antibiotic resistance in Mycobacterium abscessus and highlights potential targets for improving antibiotic efficacy.

This paper introduces PCL analysis to predict small molecule mechanisms of action in Mycobacterium tuberculosis using PROSPECT data, achieving high sensitivity and precision in MOA prediction.

This paper develops an engineered Mycobacterium tuberculosis strain with kill switches for a safe TB human challenge model, showing rapid clearance and low escape rates.

The paper uses deep learning to predict drug accumulation in Mycobacterium abscessus, finding that chemical properties alone are insufficient and that models trained on experimental data can accurately predict accumulation for diverse compounds.

The paper shows that phylogenetic clustering in Mycobacterium abscessus is linked to reduced mutation rates and DNA repair gene variation, suggesting adaptation rather than transmission as the cause.

This study identifies genetic requirements for growth and virulence in Mycobacterium avium subsp. hominissuis using transposon mutagenesis, revealing shared and unique genes with M. tuberculosis.